Evidence map›Paper›PMID 26695865›Full record

ArticleJournal of labelled compounds & radiopharmaceuticals2016

Efficient automated syntheses of high specific activity 6-[18F]fluorodopamine using a diaryliodonium salt precursor.

Kiel D Neumann, Linlin Qin, Amy L Vāvere, Bin Shen, Zheng Miao, Frederick T Chin, Barry L Shulkin, Scott E Snyder, Stephen G DiMagno

Abstract read
In one paragraph

Article in Journal of labelled compounds & radiopharmaceuticals, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. FacileNature protocols · 2019
    Article
  3. Hypervalent aryliodine compounds as precursors for radiofluorination.Journal of labelled compounds & radiopharmaceuticals · 2018
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kiel D NeumannDepartment of Chemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.
Linlin QinDepartment of Chemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.
Amy L VāvereDivision of Nuclear Medicine, Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Bin ShenDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Zheng MiaoDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Frederick T ChinDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Barry L ShulkinDivision of Nuclear Medicine, Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Scott E SnyderDivision of Nuclear Medicine, Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Stephen G DiMagnoDepartment of Chemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.
Stanford University · USSt. Jude Children's Research Hospital · USUniversity of Nebraska–Lincoln · US

Funding

Small Animal ImagingP50CA114747 · NCI · STANFORD UNIVERSITY · PI GAMBHIR, SANJIV S · 2005 to 2014
$18.2M
Synthesis of Radiofluorinated PET Imaging AgentsR01EB015536 · NIBIB · UNIVERSITY OF NEBRASKA LINCOLN · PI DIMAGNO, STEPHEN · 2012 to 2015
$1.2M
NCI NIH HHS P50 CA114747NIBIB NIH HHS R01 EB015536NIBIB NIH HHS R01EB015536
6 · The paper itself

Abstract

6-[(18)F]Fluorodopamine (6-[(18) F]F-DA) is a positron emission tomography radiopharmaceutical used to image sympathetic cardiac innervation and neuroendocrine tumors. Imaging with 6-[(18)F]F-DA is constrained, in part, by the bioactivity and neurotoxicity of 6-[(19)F]fluorodopamine. Furthermore, routine access to this radiotracer is limited by the inherent difficulty of incorporation of [(18)F]fluoride into electron-rich aromatic substrates. We describe the simple and direct preparation of high specific activity (SA) 6-[(18)F]F-DA from no-carrier-added (n.c.a.) [(18)F]fluoride. Incorporation of n.c.a. [(18)F]fluoride into a diaryliodonium salt precursor was achieved in 50-75% radiochemical yields (decay corrected to end of bombardment). Synthesis of 6-[(18)F]F-DA on the IBA Synthera® and GE TRACERlab FX-FN automated platforms gave 6-[(18)F]F-DA in >99% chemical and radiochemical purities after HPLC purification. The final non-corrected yields of 6-[(18)F]F-DA were 25 ± 4% (n = 4, 65 min) and 31 ± 6% (n = 3, 75 min) using the Synthera and TRACERlab modules, respectively. Efficient access to high SA 6-[(18)F]F-DA from a diaryliodonium salt precursor and n.c.a. [(18)F]fluoride is provided by a relatively subtle change in reaction conditions - replacement of a polar aprotic solvent (acetonitrile) with a relatively nonpolar solvent (toluene) during the critical radiofluorination reaction. Implementation of this process on common radiochemistry platforms should make 6-[(18)F]F-DA readily available to the wider imaging community.

Indexed as

Chemistry Techniques, SyntheticDopamineOnium CompoundsRadiopharmaceuticals6-fluorodopamineDopamineOnium CompoundsRadiopharmaceuticals6-[18F]fluorodopaminediaryliodonium saltsemission computed tomographyfluorine-18positron emission tomography

Identifiers

PMID26695865
PMCPMC4715522
OpenAlexW2209293639

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.